Immunotherapy combo shows promise in cervical cancer trial

NCT ID NCT03298893

Completed Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study tested whether adding the immunotherapy drug nivolumab to standard chemoradiation is safe for people with locally advanced cervical cancer. Twenty-one adults received nivolumab alongside cisplatin and radiation, followed by up to six months of nivolumab alone. The main goal was to check for serious side effects, with a secondary look at how well the cancer responded.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (a cancer immunotherapy drug) combined with cisplatin chemotherapy and radiation therapy
What this could lead to: If successful, this combination could improve outcomes for locally advanced cervical cancer by adding immunotherapy to standard chemoradiation.
What could go wrong: This is a small, early-phase study (21 participants) focused on safety, not proof of effectiveness. Adding immunotherapy may increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER LOCALLY ADVANCED CERVICAL CANCER

Contacts and locations

Locations

Hopital Européen Georges Pompidou

Paris, 75015, France
Institut Curie

Paris, 75005, France
Institut Curie Hopital René Huguenin

Saint-Cloud, 9220, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.